+594.2%
ETN vs MRNA
+554.4%
+39.8%
-44.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.0% | +5.4% | -1.4% | +3.8% |
| 7D | +3.5% | -1.1% | +4.6% | +3.6% |
| 30D | -7.5% | +126.1% | -133.6% | -11.3% |
| 3M | +8.3% | +190.0% | -181.7% | +2.3% |
| 6M | +20.2% | +157.2% | -137.0% | +14.0% |
| YTD | +34.7% | +388.2% | -353.5% | +23.3% |
| 1Y | +19.4% | +467.0% | -447.6% | +8.3% |
| 3Y | +85.5% | +36.1% | +49.4% | +75.1% |
| 5Y | +186.6% | -68.0% | +254.6% | +170.7% |
| All | +594.2% | +554.4% | +39.8% | +530.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling